An article in the Sept. 13, 1996, issue of BioWorld Today on AronexPharmaceuticals Inc., of The Woodlands, Texas, should have said thecompany's Phase II trial of TretinoidLF for acute promyelocyticleukemia is expected to be complete by the end of 1997.

(c) 1997 American Health Consultants. All rights reserved.

No Comments